AgSept - Innovative Drug against viral diseases like pneumonia, Covid, or Rabies

Business case (example India)

Potential:
Project 1:
Fifty percent of the world's pneumonia deaths occur in India which means approximately 3.7 lakh (370 000) children die of pneumonia annually in India. Worldwide Pneumonia accounts for 14% of all deaths of children under 5 years old, killing 740 180 children in 2019. In 2021 3.3 million Pneumonia cases have been estimated for India. The aver-age cost per patient in management of pneumonia was 12,245 ± 593 INR ($187.34 ± 9.07). The mean cost of anti-biotics was 3823.602 ± 456 INR ($58.50 ± 6.97) as compared to other drugs which cost 1069.742 ± 561 INR ($16.36 ± 8.58).
If drug costs of over 50 $ are accepted to treat pneumonia, this should be considered the target price for our product. Assume 30% of the cases are viral origin, then the treatment of ca. 1 Mio patients per year would result in an annual turnover of 50 Mio $ in India alone.

Project 2:
Rabies is transmitted through the bite of animals infected with rabies, primarily dogs. Globally, dog mediated rabies causes an estimated 59,000 human deaths annually. According to WHO, India accounts for 36% of the global deaths due to rabies. India also accounts for 65% of the deaths due to rabies in the SouthEast Asia region.
Managing a rabies exposure, by prophylaxis (PEP) is currently estimated at an average of US$ 108 costs. Every year, more than 29 million people worldwide receive PEP. This is estimated to prevent hundreds of thousands of rabies deaths annually. Globally, the economic burden of dog-mediated rabies is estimated at US$ 8.6 billion per year, in addition to uncalculated psychological trauma for individuals and communities.
A possible assumption might be, that besides the expensive Prophylaxis, our treatment can be given after infection and therefore makes the PEP omittable. The number of doses of our innovative product that need be administered per year, should then go into millions, at low prices per dose (e.g., 10 $), so that they can be afforded by affected families that often have a daily income below 2 $. At these prices the yearly turnover can reach 10 Mio $ very easily.

Desired business relationship

Technology selling

Patent licensing

Investor will get ownership of the whole project.

Investor will have the lead and plays the active role in the development. BHS Medical solutions supports with expertise and production of the formulation in the first stages, apart from that it plays the passive role.

2 steps Approach:

1. Initial agreement and lump sum payment (250 000 $)
   for first information package, for transfer of IP and other rights.
2. Subsequently, payment based on the sales volume of the medicinal product
   after market launch, on a commission base (e.g. 5% of the net sales revenue).
   Open books regulation has to apply.

Duration of the contract minimum 5 years, to provide time for studies and market penetration.

Applications

Unique formulation containing Silver nanoparticles (AgNP) with superior antiviral efficacy

Project 1: Anti Pneumonia (Viral related)

Project 2: Anti Rabies Virus

Current development status

Laboratory prototypes

Project 1 is currently at TRL level 5 – 6, and project 2 can be considered at TRL level 4.

Publication: Reduction in the COVID-19 pneumonia case fatality rate by silver nanoparticles: A randomized case study: Heliyon. https://doi.org/10.1016/j.heliyon.2023.e14419. See Document attached.

The used substance underwent an extended toxicological and human health risk analysis. Study reports and summary will be provided after finalization of our agreement.